San Carlos-based Protuoso Biosciences announced the close of an oversubscribed USD 9.5 million seed financing round to advance its MUXBODY fusion protein platform across cardiometabolic, oncology, and autoimmune indications, with no prior disclosed institutional financing on record.
The round was co-led by Taya Venture and Darwin Ventures, with participation from NSG Ventures, SEEDS, and undisclosed additional investors. No placement agent or underwriter was involved, consistent with a private seed-stage transaction. No insider participation was disclosed. The oversubscribed status indicates investor demand exceeded the targeted raise, though the company did not disclose the original fundraising target or the final investor count. Proceeds are earmarked for platform development and pipeline advancement across the three named therapeutic areas.
Company overview and pipeline
Protuoso Biosciences is a pre-clinical biotechnology company organized around a 'hub-and-spoke' structure in which a central protein engineering platform generates multiple therapeutic assets, each of which can be advanced, partnered, or spun out independently. The core technology consists of MUXBODIES, described as fully recombinant fusion proteins that integrate antibodies, cytokines, peptides, and other signaling modules into single molecules capable of engaging multiple biological mechanisms simultaneously. The platform incorporates computational protein design, massively parallel synthetic biology, and AI-enabled modular engineering to optimize multi-domain constructs.